Urovant Sciences is advancing urologic patient care by delivering and developing innovative therapies.
Urovant Sciences is a biopharmaceutical company advancing urologic patient care through development of innovative therapies and exceptional licensing opportunities.
Our goal is to be the leading specialty company, recognized and trusted by patients and providers for our commitment to urology and their well-being. Urologic conditions can have a major impact on daily life, with those affected often suffering in silence as their conditions are overlooked, misunderstood or not adequately treated.
More than 30 million people in the U.S. live with the bothersome symptoms of overactive bladder (OAB). The FDA has approved Gemtesa® (vibegron) for the treatment of overactive bladder in adult patients.
Urovant Sciences Presents Positive Ambulatory Blood Pressure Data Showing That GEMTESA® (vibegron) 75 mg in Overactive Bladder Was Not Associated with Statistically Significant or Clinically Meaningful Effects on Blood Pressure or Heart Rate
Urovant Sciences to Present New Ambulatory Blood Pressure Data in Patients Dosed With GEMTESA® (vibegron) 75 mg for Overactive Bladder at the Virtual 2021 Annual Meeting of the American Urological Association